secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001104659-24-124279
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee: APG808 Phase 1 shows 55-day half-life; APG777 data support annual dosing; Phase 2 topline now mid-2025
--------------------------------------------------------------------------------

- APG808 interim Phase 1: half-life ~55 days, supports every 2-3 month dosing; well-tolerated; Phase 1b in asthma expected 1H 2025.
- APG777 Phase 1 12-month data: half-life 77 days, near complete pSTAT6 inhibition, supports potential annual dosing in AD.
- APG777 Phase 2 Part A 16-week topline data accelerated to mid-2025 due to strong enrollment.
- Preclinical PoC for APG777+APG990 combo: Phase 1b vs DUPIXENT in AD planned for 2025, data 2H 2026.
- APG333 (anti-TSLP) Phase 1 start by end 2024; combo with APG777 in asthma/COPD under planning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/0001104659-24-124279-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465924124279/tm2429855d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-124279

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer